➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School

Last Updated: August 5, 2020

DrugPatentWatch Database Preview

TOBREX Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Tobrex, and when can generic versions of Tobrex launch?

Tobrex is a drug marketed by Novartis and Sandoz Inc and is included in three NDAs.

The generic ingredient in TOBREX is tobramycin. There are eighteen drug master file entries for this compound. Twenty-eight suppliers are listed for this compound. Additional details are available on the tobramycin profile page.

US ANDA Litigation and Generic Entry Outlook for Tobrex

A generic version of TOBREX was approved as tobramycin by BAUSCH AND LOMB on November 29th, 1993.

  Start Trial

Drug patent expirations by year for TOBREX
Drug Prices for TOBREX

See drug prices for TOBREX

Drug Sales Revenue Trends for TOBREX

See drug sales revenues for TOBREX

Recent Clinical Trials for TOBREX

Identify potential brand extensions & 505(b)(2) entrants

Alcon ResearchPhase 1
Alcon ResearchPhase 3

See all TOBREX clinical trials

Pharmacology for TOBREX

US Patents and Regulatory Information for TOBREX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis TOBREX tobramycin OINTMENT;OPHTHALMIC 050555-001 Approved Prior to Jan 1, 1982 RX Yes Yes   Start Trial   Start Trial   Start Trial
Novartis TOBREX tobramycin SOLUTION/DROPS;OPHTHALMIC 050541-001 Approved Prior to Jan 1, 1982 AT RX Yes Yes   Start Trial   Start Trial   Start Trial
Sandoz Inc TOBREX tobramycin SOLUTION/DROPS;OPHTHALMIC 062535-001 Dec 13, 1984 AT RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.